Improve

Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control

According to the American Diabetes Association, the total annual economic cost of diabetes in 2002 was estimated to be $132 billion, or one out of every 10 health care dollars spent in the United States. A chronic disease with no cure, diabetes is a group of diseases (including Type 1, Type 2, and gestational) marked by...

Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis

- Multinational Phase III Study Meets Primary Endpoint inRheumatoid Arthritis Patients Who Failed to Respond to Anti-tumorNecrosis Factor Treatments - NUTLEY, N.J., July 10, 2007 /PRNewswire/ -- Roche todayannounced that results from the Actemra Radiate (RheumAtoiDArthritIs Study in Anti-TNF FailurEs) trial successfully met itsprimary endpoint in patients with moderate to severe rheumatoi...

Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia

ROCHESTER, Minn., July 2, 2007-Women with at least three sites ofcellular atypia in breast tissue are nearly eight times more likelythan average women to develop breast cancer, according to findingsof a Mayo Clinic Cancer Center led study of women with atypicalhyperplasia. The findings are published in the July 1 issue of theJournal of Clinical Oncology. Several previous studies have show...

The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients

- Data Presented at the 11th International Myeloma Workshop - NORTH HOLLYWOOD, Calif., and KOS, Greece, June 29, 2007/PRNewswire/ -- The International Myeloma Foundation (IMF) --supporting research and providing education, advocacy and supportfor myeloma patients, families, researchers and physicians -- todaysaid that updated statistics reported at the 11th InternationalMyeloma Workshop i...

Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone

-- Additional Findings Reported Safety & Tolerability Profilein Subjects with Type 2 Diabetes and Healthy Subjects -- CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- Phase III datapresented this week at the annual meeting of the American DiabetesAssociation demonstrated that saxagliptin, an inhibitor ofdipeptidyl-peptidase-4 (DPP-4) in development by Bristol-MyersSquibb Company and A...

Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone

Additional Findings Reported Safety & Tolerability Profilein Subjects with Type 2 Diabetes and Healthy Subjects CHICAGO, June 25 /PRNewswire-FirstCall/ -- Phase III datapresented this week at the annual meeting of the American DiabetesAssociation demonstrated that saxagliptin, an inhibitor ofdipeptidyl-peptidase-4 (DPP-4) in development by Bristol-MyersSquibb Company (NYSE: BMY...

ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model

KOS, Greece--(BUSINESS WIRE)--Jun 26, 2007 - Acceleron Pharma,Inc., a biopharmaceutical company developing therapeutics for thetreatment of musculoskeletal, metabolic and cancer-relateddiseases, today announced results demonstrating that ACE-011, anovel anabolic bone agent for the treatment of bone loss, preservedbone mass and architecture in a murine model of multiple myeloma.Multiple myel...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - New data from aninvestigational study released at the American Diabetes Association(ADA) 67th Annual Scientific Sessions showed that initialcombination therapy with Januvia(TM) (sitagliptin) and metformindemonstrated significant improvement in markers of beta cellfunction in patients with type 2 diabetes. Pancreatic islet betacell function determines...

DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

Top Line Data for the Treatment of Type 2 Diabetes Presented at the67th Annual Scientific Sessions of American Diabetes Association SAN FRANCISCO, June 25, 2007 /PRNewswire/ -- DiObex, Inc., aprivately-held biopharmaceutical company focused on the developmentof therapeutics to treat metabolic diseases, today announced thepresentation of top line data of its phase 2a study of DIO-902, afir...

Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinson's Disease

FORT LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Neurologix, Inc.(OTCBB:NRGX) today announced the publication in the June 23 issueof the journal The Lancet of positive results from the first evergene therapy trial for Parkinson's disease and the first report ofdirect gene transfer into a patient's own brain cells for any adultneurodegenerative disease. The open label Phase 1 study, conduct...

Three Studies Suggest Abbott's Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis

One Groundbreaking Study Showed 11 Percent Fewer RA PatientsReported Job Loss When Treated With HUMIRA Combination TherapyCompared to Methotrexate Alone BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --Rheumatoid arthritis (RA) is one of the most common causes ofdisability in the Western world. New data released today show thatrheumatoid arthritis (RA) patients treated with Abbott...

Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen

Survival Benefit Demonstrated for an AI Over Tamoxifen ina Single Trial LUTON, UK, Friday 15 June 2007: Analysis of the entirepopulation of a single trial has demonstrated that survival inearly breast cancer can be significantly improved by switching fromtamoxifen to anastrozole (Arimidex). An analysis of the'Arimidex'-'Nolvadex 95' (ARNO 95) study, published online in TheJourna...

Remicade Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation

Findings from the ASSERT Trial Presented at EULAR BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ -- Datapresented today at the European League Against Rheumatism (EULAR)Annual European Congress of Rheumatology showed that patients withankylosing spondylitis (AS) who received REMICADE(R) (infliximab)over two years experienced significant improvement in spinalmobility. In addition,...

Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care

NUTLEY, N.J., June 15, 2007 /PRNewswire/ -- Results of theOption (TOcilizumab Pivotal Trial in Methotrexate InadequaterespONders) trial, the first multinational Phase III study outsideof Japan, showed that patients treated with Actemra (either 4mg/kgor 8mg/kg) plus methotrexate achieved a significant and clinicallyimportant improvement in the signs and symptoms of moderate tosevere rheum...

Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy

BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --Bristol-Myers Squibb Company today announced results regarding theefficacy and safety of ORENCIA(R) (abatacept) from the open-labelphase of an ongoing investigational study in children with juvenileidiopathic arthritis (JIA) who have had an inadequate response toone or more disease-modifying anti- rheumatic drugs (DMARDs), suchas m...

Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo

Demonstrates Positive Effect on Objective and Subjective SleepMeasures MINNEAPOLIS, June 13, 2007 /PRNewswire-FirstCall/ -- Accordingto study results presented today at SLEEP 2007, the 21st annualmeeting of the Associated Professional Sleep Societies (APSS),VEC-162, a balanced melatonin (MT1/MT2) receptor agonist beingdeveloped by Vanda Pharmaceuticals Inc. , demonstrated improvementsin...

Ivivi's PEMF Technology Significantly Improves Neuron Survival in Parkinson's Disease Model, Study Finds

NORTHVALE, N.J.--(BUSINESS WIRE)--Jun 12, 2007 - Proprietary PulsedElectromagnetic Field (PEMF) technology, developed by IviviTechnologies, Inc. (AMEX:II), improved neuron survival in astandard animal cell model of brain inflammation, researchersreported today in a platform presentation at theBioelectromagnetics Society (BEMS,http://www.bioelectromagnetics.org) Annual Meeting, in Kanazawa,...

OREXIGEN Therapeutics Announces Sustained-Release Formulation of Zonisamide Shows Improved Tolerability When Compared to Immediate Release Formulation

Orexigen(TM) is evaluating zonisamide SR as a novel component inEMPATIC(TM) Phase IIb obesity trial SAN DIEGO, June 07, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM)Therapeutics, Inc. , a biopharmaceutical company focused on thetreatment of central nervous system disorders with an initial focuson obesity, today announced results from a Phase I trial evaluatingsafety and pharmacokinetics of...

Merck's Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study

CHICAGO--(BUSINESS WIRE)--Jun 7, 2007 - Clinical results from aPhase II study presented for the first time at the AmericanHeadache Society (AHS) annual meeting showed that MK-0974, aninvestigational oral calcitonin gene-related peptide (CGRP)receptor antagonist, significantly improved migraine pain relieftwo hours after dosing compared to placebo, and the relief wassustained through 24 hour...

New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis

Second Multinational Phase III Study Provides Further Evidence ofthe Significant Role of IL-6 Receptor Inhibition in the Treatmentof Rheumatoid Arthritis BASEL, Switzerland, June 6, 2007-Roche announced today thatToward (1), the second multinational phase III Actemra(tocilizumab) study, successfully reached its primary endpoint andshowed that a greater proportion of patients treated with...

Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - SyntaPharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical companyfocused on discovering, developing, and commercializing smallmolecule drugs to treat severe medical conditions, today announcedencouraging results from the analysis of overall survival (OS) timefor patients in the Company's double-blind, randomized, controlled,multi-center...

Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma

Data Presented at the ASCO Cancer Conference NORTH HOLLYWOOD, Calif., and CHICAGO, June 04, 2007 /PRNewswire/-- The International Myeloma Foundation (IMF)-supporting researchand providing education, advocacy and support for myeloma patients,families, researchers and physicians-today said that data from afollow-up to a Phase 3 multi- national clinical trial shows thecombination of DOXIL(R)...

Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Introgen Therapeutics, Inc.(NASDAQ: INGN) and the Company's clinical collaborators todayreported updated Phase 2 data demonstrating a significantcorrelation between abnormal p53, tumor responses and increasedsurvival following ADVEXIN(R) therapy in patients with recurrentsquamous cell carcinoma of the head and neck. The data (Abstract#6057) were prese...

Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75

Phase III Clinical Data on Thalidomide in Multiple MyelomaPresented at the American Society of Clinical Oncology 43rd AnnualMeeting CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- PharmionCorporation today reported the final results of a Phase III studydemonstrating that the addition of Thalidomide to standard therapyimproves overall survival (OS) by 17.6 months in patients aged 75or ol...

The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer

Presentation at ASCO Plenary Session Reports EORTC 40983 (EPOC)Intergroup Study Results CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Results of therandomized phase III EORTC 40983 Intergroup study, or EPOC study,demonstrate for the first time that peri-operative (pre and postsurgery) FOLFOX4 (Eloxatin(R) (oxaliplatin injection) incombination with a standard chemotherapy regimen for co...

Study Suggests Strattera Improved ADHD Symptoms in Patients With Comorbid Alcohol Abuse

Prevalence of Alcohol Abuse Among ADHD Patients Nearly Triple Thatof General Population, Affecting Approximately 1 Million People INDIANAPOLIS, May 23, 2007 /PRNewswire-FirstCall/ -- Data from arecent clinical study showed Strattera(R) (atomoxetine HCl)improved symptoms of Attention- Deficit/Hyperactivity Disorder(ADHD) in patients with comorbid alcohol abuse disorder, suggestingADHD can...

Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up

Separate Survey Underscores Impact of Disease on Work Status andProductivity WASHINGTON, May 23, 2007 /PRNewswire-FirstCall/ -- Findingspresented today at Digestive Disease Week(R) 2007 (DDW), fromlong-term extensions of the ACT trials (Active Ulcerative Colitis 1& 2) show that subjects with moderately to severely activeulcerative colitis (UC) who had responded to REMICADE(R)(inflixi...

Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide

CRANBURY, N.J., and BRISTOL, Tenn., May 22, 2007/PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and KingPharmaceuticals, Inc. reported today that data from Study 16 andStudy 17 of the Phase 2B clinical trial program evaluatingbremelanotide in men with erectile dysfunction (ED) were presentedyesterday at the American Urological Association (AUA) AnnualMeeting (AUA 2007) held in Anahe...

Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial

WASHINGTON, May 22, 2007 /PRNewswire/ -- Results from analyseslooking at factors contributing to successful treatment ofulcerative colitis (UC), were presented at Digestive Disease Week(DDW) this week. Both of these studies were funded by Procter &Gamble (P&G) Pharmaceuticals, Inc. Findings from one studyoffer new information on improvement of quality of life for UCpatients t...

Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo

Pooled Findings Presented at 2007 APA Meeting Also Showed NoSignificant Impact on Weight for Desvenlafaxine Succinate COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstCall/ --Findings from two separate pooled analyses - one examining theeffect of desvenlafaxine succinate on anxious symptoms and theother on painful symptoms associated with major depressive disorder(MDD) -- as well as a sep...

Data Suggest Cymbalta Improved Functioning in Patients with Generalized Anxiety Disorder

Relationship Between Ability to Function and Treatment of Anxiousand Painful Physical Symptoms Studied INDIANAPOLIS, May 21, 2007 /PRNewswire-FirstCall/ -- Datasuggest that patients with generalized anxiety disorder (GAD)treated with Cymbalta(R) (duloxetine HCl) experienced improvedability to perform everyday activities at home, work and in socialsituations compared to sugar pill. These i...

Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist

Findings Show Compliance with Medication Instructions butUnderscore Need for Improved Patient Communication, LifestyleManagement and More Healthcare Provider Efforts to Control ElevatedBlood Pressure NEW YORK, May 19, 2007 /PRNewswire/ -- Results of a surveyconducted by Harris Interactive(R) for the Hypertension EducationFoundation (HEF) were presented at the American Society ofHypertens...

New Study Demonstrates that Lubiprostone May Improve Symptom Relief Rates in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

WASHINGTON, May 21, 2007 /PRNewswire/ -- A new studydemonstrated that the active ingredient in Amitiza (lubiprostone),given 8 mcg twice a day, may improve symptom relief rates in adultswith irritable bowel syndrome with constipation (IBS-C). Theseresults were presented as a late-breaker at Digestive Disease Week2007, the largest annual international meeting of digestive diseasespecialist...

Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma

Adding MabThera to first line chemotherapy significantlyincreases patients_ overall survival BASEL, Switzerland (21 May, 2007) _ In a study publishedyesterday in the Journal of Clinical Oncology, MabThera (rituximab)plus chemotherapy (MCP*) was shown to significantly improvesurvival in patients with follicular lymphoma (FL) compared tochemotherapy alone.1 Follicular lymphoma is the...

First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A) Significantly Improves Idiopathic Detrusor Overactivity (IDO) in Patients With Symptoms of Overactive Bladder

Treatment Benefits Were Maintained for at Least 24 Weeks, Accordingto Report Published in The Journal of Urology LONDON, May 15, 2007 /PRNewswire/ -- Researchers from Guy'sHospital and King's College London School of Medicine haveannounced the results from the first randomized, double-blind,placebo-controlled study evaluating botulinum toxin type A (BTX-A,BOTOX(R)) as a treatment for idio...

Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication

CHICAGO, May 1, 2007—The drug levosimendan did not improvesurvival for patients with decompensated heart failure whencompared with a more widely-used treatment for this condition,dobutamine, according to a study in the May 2 issue of Acute decompensated heart failure (ADHF; severe heart failurecharacterized by inability of the heart to maintain adequate bloodci...

Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women

FRIMLEY, SURREY, England, April 30, 2007 /PRNewswire-FirstCall/-- - Femara reduces the risk of breast cancer spreading to thelungs, the brain or the bone which has a worse prognosis than whenthe cancer is localised to the breast Newly published data in the May issue of Annals of Oncology,Oxford University Press show that after two years of post-surgicaltherapy, postmenopausa...

OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer

MELVILLE, N.Y.--(BUSINESS WIRE)--Apr 25, 2007 - OSIPharmaceuticals, Inc. (Nasdaq: OSIP) announced today that resultspublished yesterday in the Journal of Clinical Oncology show thatadding Tarceva(R) (erlotinib) to gemcitabine chemotherapysignificantly improves survival when administered as first-linetherapy to patients with advanced pancreatic cancer. Data from thisstudy, conducted by the N...

GTx Announces Ostarine Improved Insulin Resistance among Elderly Patients in a Recently Completed Phase II Clinical Trial

MEMPHIS, Tenn.--(BUSINESS WIRE)--Apr 17, 2007 - GTx, Inc. (NASDAQ:GTXI) announced today that data from a recently conducted Phase IIOstarine(TM) clinical trial of 60 elderly men and 60 postmenopausalwomen revealed that insulin and glucose levels were reduced andinsulin resistance was improved among subjects receiving the 3 mgdose of Ostarine compared to baseline. These observations were even...

Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

- As previously announced, primary endpoint not met; plausiblyconfounded by survival benefit of post-study treatment with ERBITUX- NEW YORK, April 16, 2007 /PRNewswire-FirstCall/ -- ImCloneSystems Incorporated and Bristol-Myers Squibb Company todayannounced detailed results from the EPIC study - a randomized,open-label, multi-center Phase III trial - comparing ERBITUX(R)(Cetuximab) plus...